epi-Inositol, Promotion Season Now in Store and Free Sample for Testing with Factory Price
- Chemical Name: Voglibosel
- CAS No.: 83480-29-9
- Molecular Fomula: C10H21NO7
- Molecular weight：267.28
- Appearance: white solid
- Sample：Available
Send Inquiry
Download Quotation
Description of epi-Inositol
An α-Glucosidase inhibitor used as an antidiabetic.
Basic Info of epi-Inositol
Basic Info
Numbering system
Properties
Safety Info
Basic Info
| Chemical Name | Voglibose |
| Synonyms | Beigrace;Basen;Jumeal;Voglistat;AO 128;Expand |
| CAS No. | 83480-29-9 |
| Molecular Formula | C10H21NO7 |
| Molecular Weight | 267.27600 |
| PSA | 153.64000 |
| LogP | -4.10150 |
Numbering system
| UNII | S77P977AG8 |
Properties
| Appearance & Physical State | white to off-white crystalline powder |
| Density | 1.58 g/cm3 |
| Boiling Point | 601.9ºC at 760 mmHg |
| Melting Point | 162-163ºC |
| Flash Point | 274.1ºC |
| Refractive Index | 1.635 |
| Storage Condition | Store in original container in a cool dark place. |
Safety Info
| RTECS | NM7524600 |
| Safety Statements | S36/37 |
| Risk Statements | R20/21/22 |
| Hazard Codes | Xi |
What is Voglibose?
- With the progress of science and technology and the development of society, chemical products have invariably permeated our daily lives, in medicine, food, cosmetics, electronics, industry, and other areas, becoming an essential part of our lives. One such product is Voglibose which has developed particularly rapidly in recent years. Do you know about Voglibose ?
- The official answer：Voglibose is an oral hypoglycemic drug that can improve postprandial hyperglycemia in diabetes. It was successfully developed by Takeda Corporation of Japan and belongs to α-glucosidase inhibitors (drugs that achieve the hypoglycemic effect by delaying the absorption of carbohydrates in the intestine), and the mechanism of action is to inhibit the disaccharide hydrolase (α-glucosidase) that breaks down disaccharides into monosaccharides in the intestine, thus delaying the digestion and absorption of sugar, thus improving postprandial hyperglycemia. The results of exhaled hydrogen gas measurement after sucrose loading in healthy adults confirmed the inhibitory effect of this drug on the increase of blood glucose at clinical dosage. When administered orally to normal rats, it inhibited the increase of blood glucose after starch, maltose, and sucrose loading, but did not inhibit the increase of blood glucose after glucose, fructose, and lactose loading. The mechanism of action study in vitro test showed that for maltase and sucrase obtained from the small intestine of pigs and rats, the inhibition of this product was strong; on the other hand, the inhibition of α-pancreatic amylase of pigs and rats was weak, and there was no inhibition of β-glucosidase. It is competitive inhibition for the disaccharide hydrolase of sucrase-isomaltase complex in rat small intestine. It is understood that voglibose has a wide range of applications, not only for middle-aged and elderly diabetic patients, but also for patients with refractory type 2 diabetes, patients with secondary failure of sulfonylureas, diabetic patients with combined hyperlipidemia, diabetic patients with combined cardiovascular and cerebrovascular diseases, and patients with combined hyperinsulinemia. Since this product does not stimulate insulin secretion, it can reduce the harmful effects of postprandial hyperinsulinemia, reduce insulin resistance, and facilitate the prevention and treatment of metabolic syndrome such as cardiovascular complications.
What’s the application of Voglibose?
- Voglibose as a second-generation α-glucosidase inhibitor mainly selectively inhibits sucrase and maltase, and the inhibitory activity of these two enzymes is much higher than that of acarbose. Because it does not affect amylase, starch in food is converted into disaccharides in the small intestine and very little starch enters the large intestine, so gastrointestinal reactions such as bloating and increased gas occur less frequently. Voglibose is rarely absorbed as a prototype drug, and more than 98% of it is metabolized in the intestine and excreted in the feces, so it can be used for patients with mild to moderate abnormal liver function. It is more suitable for patients who have difficulty in diet control, and any dose will not cause drug factor hypoglycemia. For the treatment of diabetes Anti-diabetic drugs.
Conclusion
Sincere to the customer and in good faith of quality is our forever followed motto. It’s the basement to be a human and do business. We take all responsibility for our products and service sincerely. We are a company integrating R&D, production, and sales. The design, research, and development of pharmaceutical intermediates including more than 330 kinds of pharmaceutical intermediates such as Anti-infectives, Cardiovascular and Cerebrovascular Systems, Digestive System, Santi-tumor, Nervous System, Geriatric Drugs, and Gynecological Drugs. At the same time, we have more than 4,000 factories in strategic cooperation with nearly 50,000 chemical products, so we can provide you with a one-stop purchasing service, which greatly saves customers’ procurement costs and time.
Keywords of Voglibose
epi-Inositol , 83480-29-9, buy epi-Inositol, Vogliboselsupplier, purchase epi-Inositol, epi-Inositol cost, epi-Inositol manufacturer, order epi-Inositol, high pur epi-Inositol epi-Inositol